These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 36731920)

  • 1. Why falsified medicines reach patients: an analysis of political and economic factors in Romania.
    Nistor AL; Pisani E; Kok MO
    BMJ Glob Health; 2023 Feb; 6(Suppl 3):. PubMed ID: 36731920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying market risk for substandard and falsified medicines: an analytic framework based on qualitative research in China, Indonesia, Turkey and Romania.
    Pisani E; Nistor AL; Hasnida A; Parmaksiz K; Xu J; Kok MO
    Wellcome Open Res; 2019; 4():70. PubMed ID: 31131333
    [No Abstract]   [Full Text] [Related]  

  • 3. Legal aspects of counteracting the trafficking of falsified medicines in the european union.
    Pashkov V; Soloviov A; Olefir A
    Wiad Lek; 2017; 70(4):843-849. PubMed ID: 29064815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Falsified medicines in parallel trade].
    Muckenfuß H
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2017 Nov; 60(11):1208-1213. PubMed ID: 28905079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges in maintaining medicine quality while aiming for universal health coverage: a qualitative analysis from Indonesia.
    Hasnida A; Kok MO; Pisani E
    BMJ Glob Health; 2021 May; 6(Suppl 3):. PubMed ID: 34049935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Public health interventions to protect against falsified medicines: a systematic review of international, national and local policies.
    Hamilton WL; Doyle C; Halliwell-Ewen M; Lambert G
    Health Policy Plan; 2016 Dec; 31(10):1448-1466. PubMed ID: 27311827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The Herceptin® case : A case of falsification of medicinal products to a greater extent].
    Streit R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2017 Nov; 60(11):1203-1207. PubMed ID: 28936679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and Estimated Economic Burden of Substandard and Falsified Medicines in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis.
    Ozawa S; Evans DR; Bessias S; Haynie DG; Yemeke TT; Laing SK; Herrington JE
    JAMA Netw Open; 2018 Aug; 1(4):e181662. PubMed ID: 30646106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [securPharm e. V. - a protective shield against falsified medicines].
    Bergen M; Hoferichter R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2017 Nov; 60(11):1255-1260. PubMed ID: 28929207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current cases of falsified medicinal products within the competence of the Federal Institute for Drugs and Medical Devices (BfArM) : Case studies and extent].
    Wittstock M; Paeschke N
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2017 Nov; 60(11):1196-1202. PubMed ID: 28980029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substandard and Falsified Medicines: Proposed Methods for Case Finding and Sentinel Surveillance.
    Pisani E; Hasnida A; Rahmi M; Kok MO; Harsono S; Anggriani Y
    JMIR Public Health Surveill; 2021 Aug; 7(8):e29309. PubMed ID: 34181563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cross-sectional analysis of falsified, counterfeit and substandard medicines in a low-middle income country.
    Khurelbat D; Dorj G; Sunderland B; Sanjjav T; Bayarsaikhan E; Damdinjav D; Dorj G; Jigjidsuren A; Lkhagvasuren O; Erdenetsetseg B
    BMC Public Health; 2020 May; 20(1):743. PubMed ID: 32434489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The health consequences of falsified medicines- A study of the published literature.
    Rahman MS; Yoshida N; Tsuboi H; Tomizu N; Endo J; Miyu O; Akimoto Y; Kimura K
    Trop Med Int Health; 2018 Dec; 23(12):1294-1303. PubMed ID: 30291683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Affordability of medicines in the European Union.
    Zaprutko T; Kopciuch D; Kus K; Merks P; Nowicka M; Augustyniak I; Nowakowska E
    PLoS One; 2017; 12(2):e0172753. PubMed ID: 28241019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surveillance for falsified and substandard medicines in Africa and Asia by local organizations using the low-cost GPHF Minilab.
    Petersen A; Held N; Heide L;
    PLoS One; 2017; 12(9):e0184165. PubMed ID: 28877208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Substandard and Falsified Medicines: Influence of Different Tolerance Limits and Use of Authenticity Inquiries.
    Hauk C; Hagen N; Heide L
    Am J Trop Med Hyg; 2021 Mar; 104(5):1936-1945. PubMed ID: 33788775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Falsified Medicines-Bridging the Gap between Business and Public Health.
    Borup R; Traulsen J
    Pharmacy (Basel); 2016 Mar; 4(2):. PubMed ID: 28970389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmaceutical Regulatory Framework in Ethiopia: A Critical Evaluation of Its Legal Basis and Implementation.
    Suleman S; Woliyi A; Woldemichael K; Tushune K; Duchateau L; Degroote A; Vancauwenberghe R; Bracke N; De Spiegeleer B
    Ethiop J Health Sci; 2016 May; 26(3):259-76. PubMed ID: 27358547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sounding out falsified medicines from genuine medicines using Broadband Acoustic Resonance Dissolution Spectroscopy (BARDS).
    Alfarsi A; Caillet C; Fawbert G; Lawrence S; Krüse J; McSweeney S; O'Mahony M; Dondorp A; Newton PN; Fitzpatrick D
    Sci Rep; 2021 Jun; 11(1):12643. PubMed ID: 34135361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.